Pulmonary · PANCE / PANRE

Sarcoidosis

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Multisystem non-caseating granulomatous disease most commonly involving lungs and lymph nodes.

Also known as: sarcoid, sarcoidosis, noncaseating granuloma, Löfgren syndrome, Heerfordt syndrome

Overview

Idiopathic multisystem disorder characterized by formation of non-caseating epithelioid granulomas in affected organs — most commonly lung and intrathoracic lymph nodes, but virtually any organ can be involved.

Epidemiology

Incidence varies by race: highest in African Americans (35-80 per 100,000) and northern Europeans. Female predominance. Peak onset ages 20-40, with second peak in women 50-60. African American patients more often present with severe/multiorgan disease.

Try two board-style Sarcoidosis questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1PulmonaryMedium
A 35-year-old man undergoes a chest radiograph for a pre-employment physical that reveals asymptomatic bilateral hilar lymphadenopathy. He reports no fever, weight loss, or cough. Serum angiotensin-converting enzyme (ACE) is mildly elevated, and spirometry is normal. Which of the following is the most appropriate management?
  • AInitiate systemic corticosteroid therapy
  • BCT chest and transbronchial lymph node biopsy
  • CBronchoscopy with bronchoalveolar lavage
  • DObservation with follow-up in 3-6 months
Reveal answer & full explanation
Correct answer: D — Observation with follow-up in 3-6 months
  • AInitiate systemic corticosteroid therapy
  • BCT chest and transbronchial lymph node biopsy
  • CBronchoscopy with bronchoalveolar lavage
  • DObservation with follow-up in 3-6 months✓

Why observation with follow-up in 3-6 months is correct

  • The picture is asymptomatic Stage I sarcoidosis: symmetric bilateral hilar lymphadenopathy without infiltrates, normal spirometry, a mildly elevated ACE, and no constitutional symptoms
  • Asymptomatic Stage I disease remits spontaneously in the large majority of patients, so the standard of care is serial observation rather than treatment or invasive testing
  • Short-interval clinical and radiographic follow-up catches the minority who progress and need further evaluation

Why the others are wrong

  • Initiate systemic corticosteroid therapy — systemic steroids are reserved for significant symptoms, declining pulmonary function, hypercalcemia, or cardiac/neuro/ocular involvement, none of which are present; treating an asymptomatic patient is right-diagnosis-wrong-step
  • CT chest and transbronchial lymph node biopsy — tissue sampling is reserved for atypical or progressive presentations; pursuing it in a classic asymptomatic case is premature closure on an aggressive workup
  • Bronchoscopy with bronchoalveolar lavage — a lymphocyte-predominant lavage with an elevated CD4:CD8 ratio is supportive but not diagnostic, and confirming a classic asymptomatic Stage I picture would not change the plan of serial observation (over-testing an incidental finding)
Question 2PulmonaryMedium
A 44-year-old African American woman presents with bilateral hilar lymphadenopathy on CXR, mild dyspnea, and erythema nodosum on her shins. She has an elevated serum angiotensin-converting enzyme (ACE) level. Biopsy of a hilar lymph node shows noncaseating granulomas. Which of the following is the most appropriate initial treatment?
  • APrednisone
  • BHydroxychloroquine
  • CObservation
  • DMethotrexate
Reveal answer & full explanation
Correct answer: C — Observation
  • APrednisone
  • BHydroxychloroquine
  • CObservation✓
  • DMethotrexate

Why Observation is correct

  • This patient has stage I sarcoidosis: bilateral hilar lymphadenopathy without parenchymal infiltrates, with mild symptoms
  • Stage I sarcoidosis remits spontaneously in 60–70% of cases
  • With only mild dyspnea and erythema nodosum, observation is appropriate

Why the others are wrong

  • Prednisone — prednisone is first-line when treatment is required; indications include progressive pulmonary dysfunction, hypercalcemia, cardiac or neurologic disease, or uveitis — none of which are present here
  • Hydroxychloroquine — not a standard treatment for pulmonary sarcoidosis at this stage
  • Methotrexate — methotrexate is a second-line steroid-sparing agent, used when systemic treatment is required and steroids are not tolerated or insufficient
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Sarcoidosis outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • African American ancestry (highest US incidence)
  • Scandinavian ancestry
  • Female sex
  • Family history
  • Occupational exposures (uncertain causal role): silica, mold, agricultural dust
  • Genetic associations: HLA-DRB1, BTNL2

Pathophysiology

Hypothesized antigen-driven T-helper 1 / Th17 response leading to non-caseating granuloma formation with epithelioid macrophages and CD4+ T cells. Activated macrophages produce 1-alpha-hydroxylase → 1,25-dihydroxyvitamin D → hypercalcemia in some patients. Exact triggering antigen unknown.

Clinical presentation

Symptoms

  • Pulmonary: dry cough, dyspnea, chest discomfort (~90% have lung involvement at some point)
  • Constitutional: fatigue, fever, weight loss, night sweats
  • Skin: erythema nodosum, lupus pernio (chronic violaceous facial plaques), papules, plaques
  • Ocular: anterior uveitis (most common), posterior uveitis, conjunctival nodules, dry eyes
  • Cardiac: heart block, arrhythmias, cardiomyopathy, sudden death
  • Neurologic (neurosarcoidosis): cranial neuropathies (CN VII most common), aseptic meningitis, hypothalamic/pituitary involvement (diabetes insipidus, hypopituitarism)
  • Renal: nephrolithiasis (hypercalciuria), interstitial nephritis
  • Hepatic/splenic involvement (often asymptomatic), peripheral lymphadenopathy
  • Löfgren syndrome (acute, good prognosis): bilateral hilar lymphadenopathy + erythema nodosum + arthralgia ± fever
  • Heerfordt syndrome (uveoparotid fever): uveitis + parotitis + facial palsy + fever

Signs / physical exam

  • Crackles uncommon despite extensive parenchymal involvement
  • Skin lesions (erythema nodosum on shins, lupus pernio on face/nose)
  • Lymphadenopathy (cervical, supraclavicular)
  • Hepatosplenomegaly
  • Eye exam: uveitis, conjunctival nodules

Classic findings

Bilateral hilar lymphadenopathy on CXR in young African American or northern European patient; Löfgren triad; lupus pernio; bell's-like facial palsy.

Differential diagnosis

  • Tuberculosis — Caseating granulomas (sarcoid is non-caseating), positive AFB, upper-lobe cavitation, exposure history
  • Lymphoma — B symptoms, bulky asymmetric lymphadenopathy, biopsy required
  • Hypersensitivity pneumonitis — Exposure history (birds, mold), upper-lobe centrilobular nodules, BAL with lymphocytosis (CD4:CD8 <1, opposite of sarcoid)
  • Berylliosis — Indistinguishable histology — requires beryllium exposure history and BeLPT (lymphocyte proliferation test)
  • Fungal infections (histoplasmosis, coccidioidomycosis) — Endemic exposures, serologic and fungal cultures
  • Granulomatosis with polyangiitis — Upper airway involvement, glomerulonephritis, c-ANCA positive
  • Common variable immunodeficiency (granulomatous-lymphocytic interstitial lung disease) — Recurrent infections, hypogammaglobulinemia

Diagnostic workup

Diagnostic criteria

Clinical/radiographic presentation + biopsy showing non-caseating granulomas + exclusion of alternative causes. Löfgren syndrome and asymptomatic Stage I CXR in a young patient may be diagnosed clinically without biopsy.

Labs

  • ACE level — elevated in ~60%, neither sensitive nor specific (poor diagnostic value)
  • CBC (lymphopenia, mild anemia), CMP (hypercalcemia in ~10%, elevated alk phos)
  • 1,25-dihydroxyvitamin D (elevated; reflects granuloma alpha-hydroxylase activity)
  • 24-hour urine calcium (often elevated even with normal serum calcium)
  • Quantiferon / PPD to exclude TB before steroids
  • ECG for cardiac involvement; echocardiogram if suspected

Imaging

  • Chest radiograph — Scadding stage (0-IV): 0 normal; I bilateral hilar adenopathy; II hilar adenopathy + parenchymal disease; III parenchymal only; IV fibrosis
  • HRCT chest — perilymphatic micronodular pattern (along bronchovascular bundles, fissures, subpleural), bilateral symmetric hilar/mediastinal adenopathy
  • PET/CT — identifies occult active disease for biopsy targeting and cardiac sarcoid evaluation
  • Cardiac MRI with gadolinium for suspected cardiac sarcoid; FDG-PET for inflammatory activity

Other studies

  • Tissue biopsy showing non-caseating granulomas — preferred site: enlarged lymph node via EBUS-TBNA (high yield, low risk); skin lesion or peripheral node if accessible; transbronchial lung biopsy
  • Always exclude TB and fungi on cultures before attributing granulomas to sarcoid
  • PFTs: restrictive pattern with reduced DLCO; can also have obstruction from endobronchial involvement
  • Slit-lamp eye exam at diagnosis (uveitis can be asymptomatic)
  • Baseline ECG and consider Holter for cardiac involvement

Diagnostic algorithm

Scadding StageCXR FindingsApprox. % at Diagnosis5-Yr Spontaneous Remission
0Normal~5-10%—
IBilateral hilar lymphadenopathy~50%~75%
IIHilar lymphadenopathy + parenchymal infiltrates~25-30%~50%
IIIParenchymal infiltrates without adenopathy~10-15%~30%
IVPulmonary fibrosis (irreversible)~5%0%
Scadding radiographic staging of pulmonary sarcoidosis — predicts prognosis and likelihood of spontaneous remission.

Treatment

First-line

  • Many patients require no treatment — spontaneous remission in ~50% within 2-5 years
  • Indications for systemic therapy: progressive pulmonary disease, symptomatic Stage II/III, cardiac involvement, neurosarcoidosis, ocular disease unresponsive to topical therapy, hypercalcemia, severe constitutional symptoms
  • Corticosteroids — first-line: prednisone 20-40 mg/day initial, then slow taper over 6-12 months; minimum 1 year of therapy typical
  • Topical/local steroids for limited skin or ocular disease
  • Hydroxychloroquine 200-400 mg/day for cutaneous disease and hypercalcemia
  • NSAIDs for arthralgias of Löfgren syndrome (often self-limited)

Second-line / adjunct

  • Steroid-sparing immunosuppressants for chronic disease or steroid intolerance: methotrexate (15-25 mg weekly + folic acid), azathioprine, mycophenolate, leflunomide
  • TNF-alpha inhibitors: infliximab, adalimumab — for refractory disease, neurosarcoid, cardiac sarcoid
  • Cardiac sarcoid: corticosteroids + immunosuppressant; ICD for high-grade block or VT; pacemaker for AV block
  • Pulmonary hypertension complicating sarcoid — referral to specialist; phosphodiesterase-5 inhibitors or endothelin antagonists in select cases
  • Lung transplantation for end-stage Stage IV fibrotic disease
  • AVOID vitamin D and calcium supplementation (worsens hypercalcemia); sun exposure precautions

Complications

  • Pulmonary fibrosis (Scadding stage IV), pulmonary hypertension, aspergilloma in old cavities
  • Sudden cardiac death from arrhythmia or heart block (cardiac sarcoid)
  • Neurosarcoidosis: cranial neuropathies, hypothalamic dysfunction, seizures
  • Vision loss from chronic uveitis
  • Hypercalcemia, nephrolithiasis, AKI
  • Steroid-related adverse effects from chronic therapy

PANCE pearls

  • Löfgren syndrome (erythema nodosum + bilateral hilar adenopathy + arthralgia ± fever) carries an excellent prognosis with spontaneous remission in most patients.
  • Cardiac sarcoid and neurosarcoidosis are leading causes of sarcoid mortality — low threshold for cardiac MRI/PET when symptoms suggest involvement.
  • Hypercalcemia in sarcoid is mediated by granuloma alpha-hydroxylase converting 25-OH-D to 1,25-OH-D — treat with steroids and AVOID vitamin D supplementation.
  • ACE level is too insensitive and nonspecific to diagnose or monitor sarcoid — do not rely on it.
  • Biopsy is essential to confirm non-caseating granulomas and exclude TB, fungi, and lymphoma before committing to immunosuppression.

References

  • ATS 2020 — Diagnosis and Detection of Sarcoidosis: An Official ATS Clinical Practice Guideline (Crouser et al., Am J Respir Crit Care Med 2020)
  • ERS 2021 — ERS Clinical Practice Guidelines on Treatment of Sarcoidosis (Baughman et al., Eur Respir J 2021)
  • WASOG — World Association of Sarcoidosis and Other Granulomatous Disorders — Cardiac Sarcoidosis Expert Consensus (Birnie et al., Heart Rhythm 2014)
  • ACCESS Study — Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis (Baughman et al., Am J Respir Crit Care Med 2001)

Practice Pulmonary questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Commonly confused with

vs Tuberculosis

Related Pulmonary diagnoses

AsthmaChronic Obstructive Pulmonary Disease (COPD)Community-Acquired Pneumonia (CAP)Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP)Aspiration Pneumonia and PneumonitisTuberculosis (Active and Latent)Pulmonary Embolism (PE)Pulmonary HypertensionPneumothorax (Spontaneous and Tension)Pleural EffusionAcute Respiratory Distress Syndrome (ARDS)Lung Cancer (Small Cell and Non-Small Cell)BronchiectasisCystic Fibrosis

Differentials & related conditions

Hypersensitivity PneumonitisPneumoconioses (Silicosis, Asbestosis, Coal Worker's, Berylliosis)

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.